Regulation of vascular endothelial growth factor by oxygen in a model of retinopathy of prematurity

Archives of Ophthalmology

Volumn 114, Issue 10, 1996, Pages 1219-1228

  Pierce, Eric A ^a,b   Foley, Eliot D ^a   Smith, Lois E H ^a,b  

^a BOSTON CHILDREN S HOSPITAL   (United States)

^b V Kann Rasmussen Res Collaborative   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

VASCULOTROPIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BLOOD VESSEL PERMEABILITY; CONTROLLED STUDY; HYPEROXIA; MOUSE; NEOVASCULARIZATION (PATHOLOGY); NONHUMAN; OXYGENATION; PRIORITY JOURNAL; RECEPTOR DOWN REGULATION; RETINA BLOOD VESSEL; RETROLENTAL FIBROPLASIA; VASCULAR ENDOTHELIUM;

EID: 0029816808     PISSN: 00039950     EISSN: None     Source Type: Journal    
DOI: 10.1001/archopht.1996.01100140419009     Document Type: Article

References (51)

1. Phelps DL. Retinopathy of prematurity: an estimate of vision loss in the United States - 1979. Pediatrics. 1981;67:924-926.
2. Pierce EA, Mukai S. Controversies in the management of retinopathy of prematurity, Int Ophthalmol Clin. 1994;34:121-148.
3. Gibson DL, Sheps SB, Uh SH, Schechter MT, McCormick AQ. Retinopathy of prematurity-induced blindness: birth weight-specific survival and the new epidemic. Pediatrics. 1990;86:405-412.
4. The Cryotherapy for Retinopathy of Prematurity Study Group. Incidence and early course of retinopathy of prematurity. Ophthalmology. 1991;98:1628-1540.
5. Manual of Procedures: Multicenter Trial of Supplemental Therapeutic Oxygen for Pre-threshold Retinopathy of Prematurity (STOP-ROP). 1991. NIH grant U10 EY09962. (Available at NIH internet site.)
6. Michaelson IC. The mode of development of the vascular system of the retina, with some observations in its significance for certain retinal diseases. Eye. 1948;68:137-180.
7. Ashton N, Ward B, Serpell G. Effect of oxygen on developing retinal vessels with particular reference to the problem of retrolental fibroplasia. Br J Ophthalmol. 1954;38:397-432.
8. Pierce EA, Avery RL, Foley ED, Aiello LP, Smith LE. Vascular endothelial growth factor/vascular permeability factor expression in a mouse model of retinal neovascularization. Proc Natl Acad Sci U S A. 1995;92:905-909.
9. Aiello LP, Pierce EA, Foley ED, et al. Suppression of retinal neovascularization in vivo by inhibition of vascular endothelial growth factor (VEGF) using VEGF-receptor chimeric proteins. Proc Natl Acad Sci U S A. 1995;92:10457-10461.
10. Hittner HM, Kretzer FL. Retiropathy of prematurity: clinical implications of retinal development. Arch Dis Child. 1988;63:1151-1167.
11. Hunter DG, Mukai S. Retinopathy of prematurity: pathogenesis, diagnosis and treatment, Int Ophthalmol Clin. 1992;32:163-184.
12. Ashton N. Oxygen and the growth and development of retinal vessels. Am J Ophthalmol. 1966;62:412-435.
13. Flynn JT, O'Grady GE, Herrera J, Kushner BJ, Cantolino S, Milam W. Retrolental fibroplasia, I: clinical observations. Arch Ophthalmol. 1977;95:217-223.
14. Weiter JJ, Zuckerman R, Schepens CL. A model for the pathogenesis of retrolental fibroplasia based on the metabolic control of blood vessel development. Ophthalmic Surg Lasers. 1981;13:1013-1017.
15. Chan-Ling T, Tout S, Hollander H, Stone J. Vascular changes and their mechanisms in the feline model of retinopathy of prematurity. Invest Ophthalmol Vis Sci. 1992;33:2128-2147.
16. Smith LEH, Wesolowski E, McLellan A, et al. Oxygen-induced retinopathy in the mouse. Invest Ophthalmol Vis Sci. 1994;35:101-111.
17. Penn JS, Tolman BL, Lowery LA. Variable oxygen exposure causes preretinal neovascularization in the newborn rat. Invest Ophthalmol Vis Sci. 1993;34: 576-585.
18. Penn JS, Tolman BL, Henry MM. Oxygen-induced retinopathy in the rat: relationship of retinal nonperfusion to subsequent neovascularization. Invest Ophthalmol Vis Sci. 1994;35:3429-3435.
19. Aiello LP, Avery RL, Arrigg PG, et al. Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders. N Engl J Med. 1994;331:1480-1487.
20. Miller JW, Adamis AP, Shima DT, et al. Vascular endothelial growth factor/vascular permeability factor is temporally and spatially correlated with ocular angiogenesis in a primate model. Am J Pathol. 1994;145:574-584.
21. Phelps DL, Rosenbaum AL. Effects of marginal hypoxemia on recovery from oxygen-induced retinopathy in the kitten model. Pediatrics. 1984;73:1-6.
22. Phelps DL. Reduced severity of oxygen-induced retinopathy in kittens recovered in 28% oxygen. Pediatr Res. 1988;24:106-109.
23. Chan-Ling T, Gock B, Stone J. Supplemental oxygen therapy: basis for non-invasive treatment of retinopathy of prematurity. Invest Ophthalmol Vis Sci. 1995;36:1215-1230.
24. Szewczyk TS. Retrolental fibroplasia and related ocular diseases classification, etiology, and prophylaxis. Am J Ophthalmol. 1953;36:1333-1361.
25. Bedrossian RH, Carmichael P, Ritter J. Effects of oxygen weaning in retrolental fibroplasia. Arch Ophthalmol. 1955;53:514-518.
26. Leung DW, Cachianes G, Kuang WJ, Goeddel DV, Ferrara N. Vascular endothelial growth factor is a secreted angiogenic mitopen. Science. 1989;246: 1306-1309.
27. Brown LF, Yeo KT, Berse B, et al. Expression of vascular permeability factor (vascular endothelial growth factor) by epidermal keratinocytes during wound healing. J Exp Med. 1992;176:1375-1379.
28. Berse B, Brown LF, Van de Water L, Dvorak HF, Senger DR. Vascular permeability factor (vascular endothelial growth factor) gene is expressed differentially in normal tissues, macrophages, and tumors. Mol Biol Cell. 1992;3:211-220.
29. Harada S, Nagy JA, Sullivan KA, et al. Induction of vascular endothelial growth factor expression by prostaglandin E2 and E1 in osteoblasts. J Clin Invest. 1994;93:2490-2496.
30. Nagy JA, Masse EM, Herzberg KT, et al. Pathogenesis of ascites tumor growth: vascular permeability factor, vascular hyperpermeability, and ascites fluid accumulation. Cancer Res. 1995;55:360-368.
31. Qu-Hong, Nagy JA, Senger DR, Dvorak HF, Dvorak AM. Ultrastructural localization of vascular permeability factor/vascular endothelial growth factor (VPF/VEGF) to the abluminal plasma membrane and vesiculovacuolar organelles of tumor microvascular endothelium. J Histochem Cytochem. 1995;43:381-389.
32. D'Amato R, Wesolowski E, Smith LEH. Microscopic visualization of the retina by angiography with high-molecular-weight fluorescein-labeled dextrans in the mouse. Microvasc Res. 1993;46:135-142.
33. Conlon RA, Herrmann BG. Detection of messenger RNA by in situ hybridization to postimplantation embryo whole mounts. Methods Enzymol. 1993;225:373-383.
34. Hemmati-Brivanlou A, Frank D, Bolce M, Brown BD, Sive HL, Harland RM. Localization of specific mRNAs in Xenopus embryos by whole-mount in situ hybridization. Development. 1990;110:325-333.
35. Coutinho LL, Morris J, Ivarle R. Whole mount in situ detection of low abundance transcripts (qmf1) and protein (MHC) in quail embryos using light and confocal laser scanning microscopy. Biotechniques. 1992;13:722-724.
36. Laemmli UK. Cleavage of structural proteins during assembly of the head of bactertiophage T4. Nature. 1970;227:680-685.
37. Towbin H, Stahelen T, Gordon J. Electrophoretic transfer of proteins from polyacrylamide gels to nitrocellulose sheets: procedure and some applications. Proc Natl Acad Sci U S A. 1979;76:4350-4354.
38. Harlow E, Lane D. Antibodies: A Laboratory Manual. Cold Spring Harbor, NY: Cold Spring Harbor Laboratory Press; 1988.
39. Chomczynski P, Sacchi N. Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal Biochem. 1987;162: 156-159.
40. Sambrook J, Fritsch EF, Maniatis T. Molecular Cloning: A Laboratory Manual. Cold Spring Harbor, NY: Cold Spring Harbor Laboratory Press; 1989.
41. Arcellana-Panlilio MY, Schultz GA. Analysis of messenger RNA. Methods Enzymol. 1993;225:303-328.
42. Feinberg AP, Vogelstein B. A technique for radiolabeling DNA restriction endonuclease fragments to high specific activity. Anal Biochem. 1983;132:6-13.
43. Laborda J. 36B4 cDNA used as an estradiol-independent mRNA control is the cDNA for human acidic ribosomal phosphoprotein PO. Nucleic Acids Res. 1991; 19:3998.
44. Delivoria-Papadopoulos M, DiGiacomo JE. Oxygen transport and delivery. In: Polin RA, Fox WW, eds. Fetal and Neonatal Physiology. Philadelphia, Pa: WB Saunders Co; 1992:801-813.
45. Char-Ling T, Gock B, Stone J. The effect of oxygen on vasoformative cell division: evidence that physiologic hypoxia is the stimulus for normal retinal vasculogenesis. Invest Ophthalmol Vis Sci. 1995;36:1201-1214.
46. Stone J, Itin A, Alon T, et al. Development of retinal vasculature is mediated by hypoxia-induced vascular endothelial growth factor (VEGF) expression by neuroglia. J Neurosci. 1995;15:4738-4747.
47. Alon T, Hemo I, Itin A, Pe'er J, Stone J, Keshet E. Vascular endothelial growth factor acts as a survival factor for newly formed retinal vessels and has implications for retinopathy of prematurity. Nat Med. 1995;1:1024-1028.
48. Collins MK, Perkins GR, Rodriguez-Tarduchy G, Nieto MA, Lopez-Rivas A. Growth factors as survival factors: regulation of apoptosis. Bioessays. 1994;16:133-138.
49. Folkman J. How is blood vessel growth regulated in normal and neoplastic tissue? Cancer Res. 1986;46:467-473.
50. Folkman J, Klagsbrun M. Angiogenic factors. Science. 1987;235:442-446.
51. Miller JW, Shima DT, Tolentino M, et al. Inhibition of VEGF prevents ocular neovascularization in a monkey model. Invest Ophthalmol Vis Sci. 1995;36: S401. Abstract.